Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 in Agitation Associated With Dementia
NCT05271552Phase 3Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in agitation (3 arms), sponsored by BioXcel Therapeutics, Inc. Primary endpoint: Positive and Negative Syndrome Scale- Excited Component at 120 minutes. Started Apr 2022; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05271552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271552.